MARKET

PTN

PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4622
+0.0095
+2.10%
After Hours: 0.4500 -0.0122 -2.64% 17:49 12/04 EST
OPEN
0.4600
PREV CLOSE
0.4527
HIGH
0.4623
LOW
0.4515
VOLUME
808.15K
TURNOVER
--
52 WEEK HIGH
0.8248
52 WEEK LOW
0.3550
MARKET CAP
106.26M
P/E (TTM)
-4.9752
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Here is What Hedge Funds Think About Palatin Technologies, Inc. (PTN)
Insider Monkey · 5d ago
Palatin Technologies (PTN) Surges: Stock Moves 8% Higher
Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Zacks · 11/19 16:11
Palatin Technologies down 3% on Q3 earnings miss
Palatin Technologies ([[PTN]] -2.4%) reports Q3 results:Net loss: ($3.9M) (+13.3%); loss/share: ($0.02) (unch); Cash and cash equivalents: $86.6M.Phase 2 study data of PL9643 for the treatment of dry eye disease on track for December
Seekingalpha · 11/17 15:45
Palatin Technologies, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 17, 2020 / Palatin Technologies, Inc. (NYSE:PTN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on November 17, 2020 at 11:00 AM Eastern Time.
ACCESSWIRE · 11/17 14:16
Palatin Technologies Q1 Adj. EPS $(0.02) Beats $(0.03) Estimate, Sales $(288.56K) Miss $1.00M Estimate
Palatin Technologies (AMEX:PTN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is unchanged from the same period last year. The company
Benzinga · 11/17 12:30
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update
, /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its first quarter ended .
PR Newswire - PRF · 11/17 12:30
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update
PR Newswire · 11/17 12:30
Dan Loeb makes new bets on Pinterest, Palantir and PG&E — Here are the highlights
Third Point released its positions from the end of the third quarter, showing a fund with more than $9.9 billion in equity positions. 
CNBC.com · 11/16 14:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTN. Analyze the recent business situations of PALATIN TECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTN stock price target is 2.167 with a high estimate of 3.000 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.69M
% Owned: 19.44%
Shares Outstanding: 229.90M
TypeInstitutionsShares
Increased
32
4.81M
New
20
1.36M
Decreased
17
1.34M
Sold Out
6
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
Independent Director
Angela Rossetti
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PTN
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.